CARLSBAD, Calif., April 12 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that it will conduct a series of four conference calls focused on the drugs in Isis' development pipeline. The first call of the series will focus on Isis' cardiovascular franchise and will be held on Wednesday, April 14, 2010 at 12:00 p.m. ET. This call will be archived for a limited time on Isis' Web site.
Conference Call
At 12:00 p.m. Eastern Time Wednesday, April 14, 2010, Isis will conduct a live webcast conference call. Interested parties may listen to the call by dialing 866-362-4829 and refer to passcode "ISIS 2010" or access the webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.
CONTACT: Kristina Lemonidis, Director, Corporate Communications,
+1-760-603-2490, or Amy Blackley, Ph.D., Assistant Director, Corporate
Communications, +1-760-603-2772, both of Isis Pharmaceuticals, Inc.
Web site: http://www.isispharm.com/
